Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
E-Z-Paque
×
Overview
What is E-Z-Paque?
Liquid E-Z-PAQUE (barium sulfate) is a radiographic contrast agent
supplied as a white to lightly colored barium sulfate suspension (60%w/v)
for oral administration. The active ingredient barium sulfate is designated
chemically as BaSO with a molecular weight
of 233.4 g/mol, a density of 4.5 g/cm,
and the following chemical structure:
Liquid E-Z-PAQUE oral suspension:
213 grams of barium sulfate supplied as a suspension (60 % w/v) in
a single-dose bottle.
What should I talk to my health care provider before I take E-Z-Paque?
How should I use E-Z-Paque?
Liquid E-Z-PAQUE is indicated for use in
single contrast radiographic examinations of the esophagus, stomach,
and small bowel to visualize the gastrointestinal (GI) tract in adult
and pediatric patients.
The
optimal oral dose of Liquid E-Z-PAQUE will vary depending on the size
and anatomy of the patient and the procedure being performed. The
recommended oral dose of Liquid E-Z-PAQUE:
What interacts with E-Z-Paque?
Sorry No Records found
What are the warnings of E-Z-Paque?
Sorry No Records found
What are the precautions of E-Z-Paque?
Sorry No Records found
What are the side effects of E-Z-Paque?
Sorry No records found
What should I look out for while using E-Z-Paque?
Liquid E-Z-PAQUE is contraindicated in patients
with the following conditions:
What might happen if I take too much E-Z-Paque?
Sorry No Records found
How should I store and handle E-Z-Paque?
Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.A Schedule CII Narcotic.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.A Schedule CII Narcotic.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.A Schedule CII Narcotic.How SuppliedProvided as: 24 x 355 mL bottles (NDC 32909-186-02).Storage and HandlingHow SuppliedProvided as: 24 x 355 mL bottles (NDC 32909-186-02).Storage and HandlingHow SuppliedProvided as: 24 x 355 mL bottles (NDC 32909-186-02).Storage and Handling
×
Clinical Information
Chemical Structure
No Image found
Clinical Pharmacology
Due to its high atomic number, barium (the active ingredient in Liquid
E-Z-PAQUE) is opaque to x-rays and therefore acts as a positive contrast
agent for radiographic studies.
Non-Clinical Toxicology
Liquid E-Z-PAQUE is contraindicated in patients
with the following conditions:
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible children.
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
Leucovorin may enhance the toxicity of fluorouracil (see
).
Barium sulfate preparations contain a number of excipients, including
natural and artificial flavors and may induce serious hypersensitivity
reactions. The manifestations include hypotension, bronchospasm and
other respiratory impairments, dermal reactions including rashes,
urticaria and itching. A history of bronchial asthma, atopy or a
previous reaction to a contrast agent may increase the risk for hypersensitivity
reactions. Emergency equipment and trained personnel should be immediately
available for treatment of a hypersensitivity reaction.
The following adverse reactions have been
identified from spontaneous reporting or clinical studies of barium
sulfate administered orally. Because the reactions are reported voluntarily
from a population of uncertain size, it is not always possible to
reliably estimate their frequency or to establish a causal relationship
to drug exposure:
×
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Clonazepam Description
Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake.
Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula:
C15H10ClN3O3 M.W. 315.72
×
Tips
Tips
×
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib).
228 major drug interactions (854 brand and generic names)
210 moderate drug interactions (691 brand and generic names)
2 minor drug interactions (4 brand and generic names)
Show all medications in the database that may interact with Imbruvica (ibrutinib).
